Analyst Reco. Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-29 EDT			5-day change	1st Jan Change
29.25 ^USD	-0.24%		-0.34%	-9.44%

04-11	Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy	MT
04-03	Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mizuho Securities Cuts Price Target on Harmony Biosciences to $40 From $42, Maintains Buy Rating	02-27	MT
Needham Cuts Price Target on Harmony Biosciences to $50 From $53, Maintains Buy Rating	02-23	MT
Mizuho Boosts PT on Harmony Biosciences to $42 From $33 Ahead of Q4 2023 Earnings Announcement, Maintains Buy Rating	02-15	MT
Goldman Sachs Adjusts Price Target on Harmony Biosciences Holdings to $28 From $25, Maintains Sell Rating	01-09	MT
BofA Securities Downgrades Harmony Biosciences Holdings to Underperform From Neutral	01-02	MT
Mizuho Raises Price Target on Harmony Biosciences to $33 From $28 on 'Continued Commercial Execution', Reiterates Buy Rating	11-06	MT
Raymond James Adjusts Price Target on Harmony Biosciences to $27 From $26, Maintains Outperform Rating	11-01	MT
Mizuho Slashes Price Target on Harmony Biosciences to $28 From $54, Keeps Buy Rating	23-10-19	MT
Needham Cuts Price Target on Harmony Biosciences to $53 From $66, Keeps Buy Rating	23-10-16	MT
Raymond James Adjusts Price Target on Harmony Biosciences to $26 From $58, Keeps Outperform Rating	23-10-16	MT
Goldman Sachs Downgrades Harmony Biosciences Holdings to Sell From Neutral, Cuts Price Target to $31 From $40	23-09-25	MT
Berenberg Initiates Coverage on Harmony Biosciences at Buy, $59 Price Target	23-09-07	MT
Raymond James Adjusts Price Target on Harmony Biosciences to $58 From $62, Maintains Outperform Rating	23-08-02	MT
Mizuho Securities Cuts Price Target on Harmony Biosciences to $54 From $60, Maintains Buy Rating	23-08-02	MT
Cantor Fitzgerald Adjusts Price Target on Harmony Biosciences Holdings to $75 From $71, Maintains Overweight Rating	23-05-03	MT
BofA Securities Initiates Coverage on Harmony Biosciences With Neutral Rating, $35 Price Target	23-04-20	MT
Goldman Sachs Adjusts Price Target on Harmony Biosciences Holdings to $43 From $49, Maintains Neutral Rating	23-02-22	MT
Needham Trims Price Target on Harmony Biosciences Holdings to $67 From $70, Keeps Buy Rating	23-02-22	MT
Mizuho Adjusts Price Target on Harmony Biosciences to $60 From $70, Reiterates Buy Rating	23-02-22	MT
Piper Sandler Adjusts Harmony Biosciences Holdings Price Target to $70 From $62, Maintains Overweight Rating	23-01-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Analyst Reco.

Filters